Intestinal transport of aminopterin enantiomers in dogs and humans with psoriasis is stereoselective: Evidence for a mechanism involving the proton-coupled folate transporter

Journal of Pharmacology and Experimental Therapeutics

Volumn 342, Issue 3, 2012, Pages 696-708

  Menter, Alan ^a   Thrash, Breck ^a   Cherian, Christina ^b   Matherly, Larry H ^b   Wang, Lei ^c   Gangjee, Aleem ^c   Morgan, Joel R ^d   Maeda, Dean Y ^d   Schuler, Aaron D ^d   Kahn, Stuart J ^d   Zebala, John A ^d  

^a BAYLOR RESEARCH INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUQUESNE UNIVERSITY   (United States)

^d SYNTRIX BIOSYSTEMS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPTERIN; PROTON COUPLED FOLATE TRANSPORTER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BIOEQUIVALENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOG; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TRANSPORT; DRUG UPTAKE; ENANTIOMER; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; MALE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; STEREOCHEMISTRY;

ADMINISTRATION, ORAL; ADULT; AMINOPTERIN; ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL TRANSPORT; CELLS, CULTURED; CHO CELLS; CRICETINAE; CROSS-OVER STUDIES; DOGS; FEMALE; HUMANS; INTESTINAL ABSORPTION; INTESTINES; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; PROTON-COUPLED FOLATE TRANSPORTER; PSORIASIS; STEREOISOMERISM; YOUNG ADULT;

EID: 84865168144     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.195479     Document Type: Article

References (43)

1. Balthasar JP (1999) Bioequivalence and bioequivalency. Am J Pharm Educ 63:194-198.
2. Cockcroft DW and Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
3. Cole PD, Beckwith KA, Vijayanathan V, Roychowdhury S, Smith AK, and Kamen BA (2009) Folate homeostasis in cerebrospinal fluid during therapy for acute lymphoblastic leukemia. Pediatr Neurol 40:34-41.
4. Cole PD, Drachtman RA, Masterson M, Smith AK, Glod J, Zebala JA, Lisi S, Drapala DA, and Kamen BA (2008) Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia. Cancer Chemother Pharmacol 62:65-75. (Pubitemid 351537847)
5. Cole PD, Drachtman RA, Smith AK, Cate S, Larson RA, Hawkins DS, Holcenberg J, Kelly K, and Kamen BA (2005) Phase II trial of oral aminopterin for adults and children with refractory acute leukemia. Clin Cancer Res 11:8089-8096. (Pubitemid 41698752)
6. Cole PD, Zebala JA, Alcaraz MJ, Smith AK, Tan J, and Kamen BA (2006) Pharmacodynamic properties of methotrexate and Aminotrexate during weekly therapy. Cancer Chemother Pharmacol 57:826-834.
7. Cramer SM, Schornagel JH, Kalghatgi KK, Bertino JR, and Horváth C (1984) Occurrence and significance of D-methotrexate as a contaminant of commercial methotrexate. Cancer Res 44:1843-1846. (Pubitemid 14145725)
8. Desmoulin SK, Wang Y, Wu J, Stout M, Hou Z, Fulterer A, Chang MH, Romero MF, Cherian C, Gangjee A, et al. (2010) Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors. Mol Pharmacol 78:577-587.
9. Fiehn C (2009) The future of folic acid anatgonist therapy in rheumatoid arthritis. Arthritis Rheum 60:1-4.
10. Flintoff WF and Nagainis CR (1983) Transport of methotrexate in Chinese hamster ovary cells: a mutant defective in methotrexate uptake and cell binding. Arch Biochem Biophys 223:433-440. (Pubitemid 13103202)
11. Folsom JP, Miller AB, Bull H, Huff B, Wright WA, and McGilligan EF (1965) Physicians' Desk Reference to Pharmaceutical Specialties and Biologicals. Medical Economics, Inc., Oradell, NJ.
12. Hendel J and Brodthagen H (1984) Entero-hepatic cycling of methotrexate estimated by use of the D-isomer as a reference marker. Eur J Clin Pharmacol 26:103-107. (Pubitemid 14152479)
13. Inoue K, Nakai Y, Ueda S, Kamigaso S, Ohta KY, Hatakeyama M, Hayashi Y, Otagiri M, and Yuasa H (2008) Functional characterization of PCFT/HCP1 as the molecular entity of the carrier-mediated intestinal folate transport system in the rat model. Am J Physiol Gastrointest Liver Physiol 294:G660-G668. (Pubitemid 351468755)
14. Kugel Desmoulin S, Wang L, Hales E, Polin L, White K, Kushner J, Stout M, Hou Z, Cherian C, Gangjee A, et al. (2011) Therapeutic targeting of a novel 6-substituted pyrrolo [2,3-d]pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate transporter. Mol Pharmacol 80:1096-1107.
15. Liegler DG, Henderson ES, Hahn MA, and Oliverio VT (1969) The effect of organic acids on renal clearance of methotrexate in man. Clin Pharmacol Ther 10:849-857.
16. Liu JP (1991) Bioequivalence and intrasubject variability. J Biopharm Stat 1:205-219.
17. Matherly LH, Hou Z, and Deng Y (2007) Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 26:111-128. (Pubitemid 46452186)
18. Matherly LH, Voss MK, Anderson LA, Fry DW, and Goldman ID (1985) Enhanced polyglutamylation of aminopterin relative to methotrexate in the Ehrlich ascites tumor cell in vitro. Cancer Res 45:1073-1078. (Pubitemid 15111262)
19. Menter A, Korman, NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, et al. (2009) Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4, Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 61:451-485.
20. McGuire JJ, Hsieh P, Coward JK, and Bertino JR (1980) Enzymatic synthesis of folylpolyglutamates. Characterization of the reaction and its products. J Biol Chem 255:5776-5788.
21. Mohsen MA (2010) A note on the calculation of intrasubject coefficient of variation in bioequivalence trials. J Bioanal Biomed 2:75-78.
22. Nakai Y, Inoue K, Abe N, Hatakeyama M, Ohta KY, Otagiri M, Hayashi Y, and Yuasa H (2007) Functional characterization of human proton-coupled folate transporter/heme carrier protein 1 heterologously expressed in mammalian cells as a folate transporter. J Pharmacol Exp Ther 322:469-476. (Pubitemid 47105788)
23. Narawa T and Itoh T (2010) Stereoselective transport of amethopterin enantiomers by the proton-coupled folate transporter. Drug Metab Pharmacokinet 25:283-289.
24. Narawa T, Shimizu R, Takano S, Tsuda Y, Ono K, Yamada H, and Itoh T (2005) Stereoselectivity of the reduced folate carrier in Caco-2 cells. Chirality 17:444-449. (Pubitemid 41395665)
25. Narawa T, Tsuda Y, and Itoh T (2007) Chiral recognition of amethopterin enantiomers by the reduced folate carrier in Caco-2 cells. Drug Metab Pharmacokinet 22:33-40.
26. Olivry T, Paps JS, Bizikova P, Murphy KM, Jackson HA, and Zebala J (2007) A pilot open trial evaluating the efficacy of low-dose aminopterin in the canine homologue of human atopic dermatitis. Br J Dermatol 157:1040-1042. (Pubitemid 47583491)
27. Piper JR and Montgomery JA (1974) A convenient synthesis of aminopterin and homologs via 6-(bromomethyl)-2,4-diaminopteridine hydrobromide. J Heterocycl Chem 11:279-280.
28. Piper JR and Montgomery JA (1977) Preparation of 6-(bromomethyl)-2,4- pteridinediamine hydrobromide and its use in improved syntheses of methotrexate and related compounds. J Org Chem 42:208-211. (Pubitemid 8105690)
29. Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, Sandoval C, Zhao R, Akabas MH, and Goldman ID (2006) Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 127:917-928. (Pubitemid 44792250)
30. Qiu A, Min SH, Jansen M, Malhotra U, Tsai E, Cabelof DC, Matherly LH, Zhao R, Akabas MH, and Goldman ID (2007) Rodent intestinal folate transporters (SLC46A1): secondary structure, functional properties, and response to dietary folate restriction. Am J Physiol Cell Physiol 293:C1669-C1678. (Pubitemid 350085626)
31. Rani S (2007) Bioequivalence: issues and perspectives. Ind J Pharmacol 39:218-255.
32. Ratliff AF, Wilson J, Hum M, Marling-Cason M, Rose K, Winick N, and Kamen BA (1998) Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies. J Clin Oncol 16:1458-1464. (Pubitemid 28175766)
33. Rees RB, Bennett JH, Hamlin EM, and Maibach HI (1964) Aminopterin for psoriasis. A decade's observation. Arch Dermatol 90:544-552.
34. Rieselbach RE, Morse EE, Rall DP, Frei E 3rd, and Freireich EJ (1963) Intrathecal aminopterin therapy of meningeal leukemia. Arch Intern Med 111:620-630.
35. Smith A, Hum M, Winick NJ, and Kamen BA (1996) A case for the use of aminopterin in treatment of patients with leukemia based on metabolic studies of blasts in vitro. Clin Cancer Res 2:69-73. (Pubitemid 26042181)
36. Swendseid ME, Swanson AL, Miller S, and Bethell FH (1952) The metabolic displacement of folic acid by aminopterin; studies in leukemia patients. Blood 7:302-306.
37. Thiersch JB and Philips FS (1949) Effects of 4-amino-pteroylglutamic acid in dogs with special reference to megaloblastosis. Proc Soc Exp Biol Med 71:484-490.
38. Von Hendy-Willson VE and Pressler BM (2011) An overview of glomerular filtration rate testing in dogs and cats. Vet J 188:156-165.
39. Wang L, Cherian C, Desmoulin SK, Polin L, Deng Y, Wu J, Hou Z, White K, Kushner J, Matherly LH, et al. (2010) Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry. J Med Chem 53:1306-1318.
40. Zebala JA (2007) inventor; Syntrix Biosystems, assignee. Facile process for the preparation of high-purity aminopterin. United States patent 7,235,660. 2007 June 26.
41. Zhao R, Diop-Bove N, Visentin M, and Goldman ID (2011) Mechanisms of membrane transport of folates into cells and across epithelia. Annu Rev Nutr 31:177-201.
42. Zhao R and Goldman ID (2007) The molecular identity and characterization of a Proton-coupled Folate Transporter-PCFT; biological ramifications and impact on the activity of pemetrexed. Cancer Metastasis Rev 26:129-139. (Pubitemid 46452187)
43. Zhao R, Matherly LH, and Goldman ID (2009) Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med 11:e4.